Key Takeaways from the Expert Call on the Evolving Cardiology Landscape

On October 20, J.P. Morgan hosted an expert call with Dr. Mark Feinberg, Cardiologist and Professor of Medicine at Harvard Medical School, to discuss the evolving cardiovascular landscape, including lipid/cholesterol management and anticoagulants, with a focus on Lp(a), PCSK9 inhibitors and Factor XI inhibitors. With detailed Lp(a)HORIZON data for pelacarsen due at AHA 2026 on November 7, Dr. Feinberg will focus on Lp(a) reduction in patients above and below 90mg/dL baseline, absolute CV risk across baseline Lp(a) quartiles and any benefit signal in high-risk subgroups;